Metabolic and hormonal effects Reproductive health Bone and cardiovascular health Neuropsychiatric considerations Future research and clinical implications Conclusion Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were initially developed to regulate blood glucose levels in patients with type 2 diabetes mellitus (T2DM)
Most of the GIP receptor targeting compounds are evaluated in vitro as stimulators of a single cellular pathway, which is the Gs-mediated cAMP production (14, 30, 37)
Lifestyle changes are essential
Even taking the DVT increase at face value, the cardiovascular benefit outweighs the clot risk by roughly 6:1
Monitor Side Effects Early symptoms like nausea or fatigue are normal and manageable
Carlin, MD, PhD, assistant professor at UC San Diego School of Medicine, in a press release